These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35833597)

  • 21. Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.
    Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
    Diabetes Obes Metab; 2017 May; 19(5):744-748. PubMed ID: 28181363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
    Marre M; Shaw J; Brändle M; Bebakar WM; Kamaruddin NA; Strand J; Zdravkovic M; Le Thi TD; Colagiuri S;
    Diabet Med; 2009 Mar; 26(3):268-78. PubMed ID: 19317822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
    Dubé MC; D'Amours M; Weisnagel SJ
    Diabetes Obes Metab; 2018 Jan; 20(1):178-184. PubMed ID: 28722271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3799-806. PubMed ID: 22855332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
    Davies MJ; Bain SC; Atkin SL; Rossing P; Scott D; Shamkhalova MS; Bosch-Traberg H; Syrén A; Umpierrez GE
    Diabetes Care; 2016 Feb; 39(2):222-30. PubMed ID: 26681713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
    Nauck MA; Petrie JR; Sesti G; Mannucci E; Courrèges JP; Lindegaard ML; Jensen CB; Atkin SL;
    Diabetes Care; 2016 Feb; 39(2):231-41. PubMed ID: 26358288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial.
    Seino Y; Kaneko S; Fukuda S; Osonoi T; Shiraiwa T; Nishijima K; Bosch-Traberg H; Kaku K
    J Diabetes Investig; 2016 Jul; 7(4):565-73. PubMed ID: 27182042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.
    Lind M; Polonsky W; Hirsch IB; Heise T; Bolinder J; Dahlqvist S; Schwarz E; Ólafsdóttir AF; Frid A; Wedel H; Ahlén E; Nyström T; Hellman J
    JAMA; 2017 Jan; 317(4):379-387. PubMed ID: 28118454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.
    Crisci I; Aragona M; Politi KS; Daniele G; Del Prato S
    Acta Diabetol; 2015 Dec; 52(6):1129-33. PubMed ID: 26293127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
    Zinman B; Gerich J; Buse JB; Lewin A; Schwartz S; Raskin P; Hale PM; Zdravkovic M; Blonde L;
    Diabetes Care; 2009 Jul; 32(7):1224-30. PubMed ID: 19289857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.
    Kaku K; Rasmussen MF; Clauson P; Seino Y
    Diabetes Obes Metab; 2010 Apr; 12(4):341-7. PubMed ID: 20380655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    Diabetes Obes Metab; 2014 Sep; 16(9):812-8. PubMed ID: 24612221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
    Vilsbøll T; Vora J; Jarlov H; Kvist K; Blonde L
    Clin Drug Investig; 2016 Apr; 36(4):293-303. PubMed ID: 26894800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).
    Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Torffvit O; Pehrsson NG
    Prim Care Diabetes; 2015 Feb; 9(1):15-22. PubMed ID: 25175385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
    Odawara M; Miyagawa J; Iwamoto N; Takita Y; Imaoka T; Takamura T
    Diabetes Obes Metab; 2016 Mar; 18(3):249-57. PubMed ID: 26661514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
    Kuhadiya ND; Malik R; Bellini NJ; Patterson JL; Traina A; Makdissi A; Dandona P
    Endocr Pract; 2013; 19(6):963-7. PubMed ID: 23807520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
    Hompesch M; Jones-Leone A; Carr MC; Matthews J; Zhi H; Young M; Morrow L; Reinhardt RR
    Diabetes Obes Metab; 2015 Jan; 17(1):82-90. PubMed ID: 25263215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.
    Galderisi A; Sherr J; VanName M; Carria L; Zgorski M; Tichy E; Weyman K; Cengiz E; Weinzimer S; Tamborlane W
    J Clin Endocrinol Metab; 2018 Mar; 103(3):1088-1094. PubMed ID: 29211871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.